A cell death program–based tumor signature stratifies prognosis, immune landscape, and therapeutic response in glioma - Takeaways - MDSpire

A cell death program–based tumor signature stratifies prognosis, immune landscape, and therapeutic response in glioma

  • By

  • Zhang, Huaichao

  • Yang, Zijiang

  • Xie, Qiang

  • Chen, Pin

  • Huang, Jinlong

  • Liu, Shuang

  • Li, Zeyang

  • Sun, Wei

  • Zhang, Xiaobiao

  • Xie, Tao

  • May 4, 2026

  • 0 min

Share

  • 1

    The study developed a pyroptosis–apoptosis–associated gene signature (PA.Sig) to predict prognosis in glioma patients.

  • 2

    PA.Sig stratified glioma patients into high- and low-risk groups, correlating with overall survival and independent prognostic value.

  • 3

    High-risk tumors exhibited increased somatic mutation burden and enriched inflammatory pathways, indicating aggressive tumor behavior.

  • 4

    Single-cell analyses revealed high-risk tumors had MES-like states and immune dysfunction despite increased immune infiltration.

  • 5

    PA.Sig serves as a prognostic biomarker and supports combinatorial strategies targeting cell death pathways and immune modulation.

Original Source(s)

A cell death program–based tumor signature stratifies prognosis, immune landscape, and therapeutic response in glioma

  • by Zhang, Huaichao , Yang, Zijiang , Xie, Qiang , Chen, Pin , Huang, Jinlong , Liu, Shuang , Li, Zeyang , Sun, Wei , Zhang, Xiaobiao , Xie, Tao

  • May 4, 2026

Related Content

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease